4D Molecular Therapeutics amends bylaws for universal proxy rules and exclusive federal forum for Securities Act claims

4D Molecular Therapeutics, Inc.

Board amended bylaws on June 14, 2022 to incorporate universal proxy rules for director nominations.
Forum selection provision changed to make U.S. federal district courts exclusive for Securities Act claims.
Amended and restated bylaws filed as Exhibit 3.1 to the 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.